7TM Pharma's Obinepitide Inhibits Food Intake in Study
Posted on: Friday, 30 November 2007, 06:00 CST
7TM Pharma has reported encouraging results from a double-blind, placebo-controlled dose-range finding Phase I/II study with obinepitide developed for the treatment of obesity and related diseases.
The study evaluated obinepitide as measured by food intake reduction. The results of the study proved that obinepitide effectively inhibits food intake thereby confirming the earlier obinepitide clinical studies. The company said that the drug candidate obinepitide has a novel mechanism of action compared to existing drugs for the treatment of obesity and it has the potential to become the first drug on the market with this mechanism.
Christian Elling, director of clinical development at 7TM Pharma, said: "With this study we have confirmed obinepitides potential to reduce food intake among the clinically obese. We especially pay attention to the effect on the food intake, as it is a significant factor in assessing an effective treatment of obesity. Compared to other candidates at a similar stage of development, this effect is very impressive."
Mr Elling also said: "Treatment of obesity is chronic, and we expect that obinepitide, being a close analog of a natural hormone, will have an attractive safety profile. It is exactly the combination of safety profile with the desired effect of weight loss that makes an attractive anti-obesity drug. At the moment we are testing obinepitide in a 28-day Phase II study with the aim of evaluating weight loss. We are looking forward to seeing these results in the first quarter of 2008."
Source: Datamonitor
Related Articles
- Reduce Relapse Thru Effective Drug Rehabilitation and Save Society Tens of Thousands of Dollars per Addict, Says Narconon
- Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
- Compellis's Collaborator Receives FDA Approval for Phase I Obesity Study
- Pramlintide and Leptin Combination Treatment Demonstrates 12.7 Percent Weight Loss in 24-Week Clinical Obesity Study
- eRx Collaborative Boosts Patient Safety With 8,000 Prescriptions Changed in June; Record Number of Electronic Prescriptions Changed As a Result of Drug-Drug and Drug-Allergy Alerts
- Kyowa Releases Results to Phase III Clinical Studies of an Anti-Parkinson's Disease Drug Istradefylline (KW-6002) Conducted Overseas
- China's Price Watchdog to See Results of Drug Price Cut
- 'I Feel Privileged to Have Had a Very Effective Drug When I Needed It' 53-Year-Old Patient Praises New Treatment for Cancer
- A Problem of Patterns Experts Blame Poor Choices for Obesity Epidemic Obesity Studies Among 113 Projects PENNINGTON BIOMEDICAL CENTER RESEARCH
- Study Identifies which Patients Will Not Respond to Treatment with Targeted Cancer Drug
 |
 |
User Comments (0)
RSS Feeds